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Multiple myeloma bone disease is characterized by an uncoupling of bone remodeling in the 
multiple myeloma microenvironment, resulting in the development of lytic bone lesions. Most 
myeloma patients suffer from these bone lesions, which not only causes morbidity but also 
negatively impacts survival. The development of novel therapies, ideally with a combined anti-
resorptive and bone-anabolic effect, is of great interest because lesions persist with the current 
standard of care, even in patients in complete remission. We have previously shown that MELK 
plays a central role in proliferation-associated high-risk multiple myeloma and its inhibition with 
OTSSP167 resulted in decreased tumor load. MELK inhibition in bone cells has not yet been 
explored, although some reports suggest factors downstream of MELK stimulate osteoclast 
activity and inhibit osteoblast activity, which makes MELK inhibition a promising therapeutic 
approach. Therefore, we assessed the effect of OTSSP167 on bone cell activity and the 
development of myeloma-induced bone disease. OTSSP167 inhibited osteoclast activity in vitro 
by decreasing progenitor viability as well as via a direct anti-resorptive effect on mature 
osteoclasts. In addition, OTSSP167 stimulated matrix deposition and mineralization by 
osteoblasts in vitro.  This combined anti-resorptive and osteoblast-stimulating effect of 
OTSSP167 resulted in the complete prevention of lytic lesions and bone loss in myeloma-
bearing mice. Immunohistomorphometric analyses corroborated our in vitro findings. In 
conclusion, we show that OTSSP167 has a direct effect on myeloma-induced bone disease in 
addition to its anti-multiple myeloma effect, which warrants further clinical development of 





The development of lytic bone lesions due to multiple myeloma bone disease (MMBD) is a 
hallmark of multiple myeloma (MM).(1) MMBD occurs in more than 80% of MM patients(2) 
and is caused by an uncoupling of bone remodeling. MMBD not only results in morbidity but 
also directly stimulates MM tumor growth through multiple mechanisms, resulting in a vicious 
cycle of bone destruction and MM growth.(3, 4) Although novel therapies continue to increase 
the life expectancy for MM patients, lytic bone lesions in these patients rarely heal.(4) 
Bisphosphonates are the current standard of care for MMBD but can be responsible of side 
effects such osteonecrosis of the jaw, renal impairment, atypical fractures and hypocalcemia.(5, 
6) These limitations highlight the need for new therapeutic strategies that ideally have a 
combined anti-MM and anti-MMBD effect.  
 We recently reported that maternal embryonic leucine zipper kinase (MELK) expression 
is strongly associated with proliferative high-risk MM and that MELK inhibition with a small 
molecule inhibitor, OTSSP167, reduces tumor load in a murine MM model.(7) Overexpression 
of MELK as well as an inverse correlation between MELK expression and survival has been 
reported for multiple malignancies.(8-10) MELK promotes cell cycle progression and interacts 
with M-phase inducer phosphatase 2 (CDC25B) and co-localizes with key cell cycle regulators 
such as cyclin B1 and cyclin-dependent kinase 1 (CDK1).(11) Downstream targets of MELK 
include the transcription factor forkhead box protein M1 (FOXM1)(12) and the histone-
methyltransferase enhancer of zeste homolog 2 (EZH2).(13) Of note, FOXM1 can also directly 
regulate MELK expression(10), presumably resulting in a positive feedback loop, and has been 
identified as a therapeutic target for high-risk MM.(14) 
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 The role of MELK and FOXM1 in osteoclasts and osteoblasts has not yet been explored. 
Regarding EZH2. Fang et al. showed that EZH2 promotes osteoclastogenesis by reducing the 
transcription factor IRF8 and subsequent upregulation of NFATC1.(15) In addition, EZH2 
prevents osteogenic differentiation of mesenchymal cells and suppression of runt-related 
transcription factor 2 (RUNX2) transcription has been implicated in this process.(16) Inhibition 
of EZH2 has been shown to mitigate bone loss in ovariectomized mice(17) and to reverse MM-
induced suppression of osteoblast differentiation in vitro.(18)  
 Because the described roles of downstream targets of MELK suggest that its inhibition 
could concurrently block osteoclast function and stimulate osteoblast function, we examined the 







OTSSP167 (Biorbyt) was dissolved in DMSO and stored at -20oC. For in vivo studies, 
OTSSP167 was dissolved in 0.5% methylcellulose (Sigma-Aldrich) and stored at -20oC. The 
following antibodies were used: anti-FOXM1 (SC-502, Santa Cruz), anti-EZH2 (#4905, Cell 
Signaling Technology) anti-MELK (GTX111958, GeneTex and 2274S, Cell Signaling 
Technology), anti-α-tubulin (T6074, Sigma), anti-GAPDH (2118, Cell Signaling Technology), 
anti-rabbit-HRP (P0217, Agilent) and anti-mouse HRP (P0260, Agilent).  
 
Cells and culture conditions 
Human peripheral blood mononuclear cells (PBMCs) were obtained after Ficoll (GE Healthcare) 
separation of whole blood. RAW264.7 cells and 5TGM.1GFP+ cells were cultured in DMEM 
(Lonza) supplemented with 10% fetal bovine serum (FBS)(Sigma-Aldrich), 2mM L-glutamine 
(Lonza) and 1% penicillin/streptomycin (P/S) (Lonza). TERT+ bone marrow mesenchymal 
stromal cells (BMSC-TERT) (kindly provided by dr. D Campana, St. Jude Children’s Research 
Hospital, Memphis, TN, USA) were cultured in RPMI-1640 (Gibco) supplemented with 10% 
FCS, 2mM L-glutamine and 1% P/S.  
 
Cell viability assay and cell cycle analysis 
RAW264.7 and PBMC viability were assessed with the cell proliferation kit I (Roche). BMSC-
TERT viability was assessed with the Cell Counting Kit 8 (Sigma-Aldrich). For cell cycle 
analysis, cells were stained using PI/RNase staining buffer (BD Biosciences), followed by FACS 




Osteoclast differentiation and in vitro bone matrix resorption 
PBMCs were seeded at a density of 750,000 cells/cm2 in alpha-MEM (Lonza) supplemented 
with 10% FCS, 2 mM L-glutamine and 1% P/S. Cells were left to adhere for 4 hours. Next, the 
medium was refreshed and supplemented with 25 ng/ml human M-CSF and 50 ng/ml human 
sRANKL (Peprotech). The culture medium was refreshed twice per week and cultures were 
stopped on day 14. RAW264.7-derived osteoclast cultures were established as described 
previously.(19) TRAP activity in osteoclast cultures was detected using the Leukocyte TRAP kit 
(Sigma-Aldrich). Alternatively, cultures were lysed for RNA or protein extraction. Bone 
resorption by osteoclasts was assessed in Osteo Assay 96-well plates (Corning) as described 
previously.(19) Actin ring formation was assessed by staining cultures with phalloidin-FITC 
(Sigma-Aldrich), followed by analysis on an A1R confocal fluorescent microscope (Nikon).  
 
Quantification of reactive oxygen species  
Reactive oxygen species (ROS) were detected using the Cellular Reactive Oxygen Species 
Detection Assay kit (Abcam). In short, cells were stained with DCDFA for 30 minutes at 37 ºC 
and fluorescence was measured (Ex/Em = 485/535 nm) on an Infinite M200 Pro plate reader 
(Tecan). 
 
Osteoblast differentiation and functional analyses 
BMSC-TERT were seeded at a density of 25,000 cells/cm2 and grown to 70–80 % confluence. 
Osteoblast differentiation was initiated by changing the medium to alpha-MEM supplemented 
with 10 % FCS, 2 mM L-glutamine, 1% P/S, 100 nM dexamethasone, 50 μg/ml ascorbic acid 
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and 3 mM β-glycerophosphate (Sigma-Aldrich). Osteogenic medium was refreshed twice per 
week. Collagen secretion and matrix mineralization were assessed by sirius red and alizarin red 
staining respectively as described previously.(19, 20) 
 
Real-time PCR 
Real-time PCR was performed as described previously (19) using 250 nmol/L of the appropriate 
primers (IDT, Supplementary table 1) or pre-designed Taqman gene expression assays (Applied 
Biosystems). Gene expression was normalized to β-actin and β2-microglubulin expression 
(osteoclasts) or RPLP0 (osteoblasts). Measurements were performed at least in triplicate and 
relative expression levels were determined using the ΔCt method.  
 
Western blotting  
Cells were lysed in RIPA Lysis and Extraction buffer (Thermo Scientific) supplemented with 
cOmplete Protease Inhibitor Cocktail (Roche). 20 μg of protein were separated by gel 
electrophoresis on a 10% SDS-polyacrylamide gel and transferred onto PVDF membranes 
(BioRad). Membranes were blocked with 5% BSA/PBS/Tween20 and incubated overnight at 
4oC with primary antibodies (MELK: 1:1000, FOXM1: 1:100, EZH2: 1:1000, α-tubulin: 1:5000, 
GAPDH: 1:2000). The next day, blots were incubated with a HRP-conjugated secondary 
antibody (1:5000), followed by visualization on an ImageQuant LAS4000 (GE Healthcare).  
 
Treatment of myeloma-bearing mice with OTSSP167 
We used the C57BL/KaLwRij 5TGM.1 mouse model (21) to assess the effect of OTSSP167 on 
the development of MMBD. Nine week-old female mice were injected i.v. with 5.0 x 105 
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5TGM.1GFP+ cells and OTSSP167 or vehicle solution was administered by oral gavage at 
different dose levels. For every cohort, mice were randomly divided into a naive group (no MM, 
n=5), a vehicle group (MM + vehicle, n=10) and a treated group (MM + OTSSP167, n=10). 
When mice showed signs of active myeloma, i.e. paraplegia, all mice within a cohort were 
sacrificed. Bone marrow plasmocytosis was determined by flushing the bones of one leg 
followed by flow cytometry on a FACSCanto flow cytometer (BD Biosciences). The femur and 
tibia of the opposite leg were defleshed and stored in 70% EtOH. Ethical approval was obtained 
for all mouse experiments (ULg license no. 1336). 
 
Micro-computed tomography 
Micro-computed tomography (μCT) was performed on distal femurs with the Skyscan 1172 
system (Bruker) as described previously.(19) 3D models of bones were generated using CTVol 
software (Bruker). The number of cortical perforations > 50 μm in diameter was counted blinded 
on reconstructed images.  
 
Bone histomorphometry 
Femurs were embedded in methylmethacrylate. All parameters were recorded as recommended 
by the American Society for Bone and Mineral Research Histomorphometry Nomenclature 
Committee.(22) Osteoblast surface and osteoid surface were measured on sections stained with 
toluidine blue and Masson’s trichrome (Sigma-Aldrich). Osteoclasts were detected by TRAP 
staining (Sigma-Aldrich) and osteoclast surface was determined. Briefly, sections were stained 
for acid phosphatase using naphthol ASTR phosphate as substrate in the presence of 50 mM 
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tartrate with hexazotised pararosaline, and counterstained with methyl green. Measurements 
were performed in NDP.View 2.6.13.  
 
Statistical analyses 
All experiments were performed at least in triplicate. Results are shown as means +/- standard 
error and representative images are shown. For comparisons of 2 means, a Student t-test was 
used. For comparisons of multiple means, a one-way ANOVA was used, followed by a 
Dunnett’s post-hoc test or Tukey’s post-hoc test. All statistical analyses were performed with 
Prism 5 (Graphpad software). P-values below 0.05 were considered significant and P-values are 





OTSSP167 hampers osteoclast differentiation 
During normal osteoclastogenesis, MELK levels increased in osteoclasts cultured from  murine 
RAW264.7 cells (Fig 1A) or from primary human mononuclear cells (results not shown) when 
compared to monocyte cultures (Fig 1A). We could confirm the earlier described (15) osteoclast 
activation pathway (EZH2-IRF8-NFATC1), by showing significant increases in EZH2, NFATC1, 
TRAP and CTSK and a decrease in IRF8 mRNA (Fig 1A). We subsequently studied the effects of 
the MELK inhibitor OTSSP167 on the proliferation of osteoclast progenitor cells and on the 
differentiation into osteoclasts. Treatment of RAW264.7 cells with 25 nM OTSSP167 for 24 
hours resulted in decreased MELK protein levels (Fig 1B).  Because of the described role of 
MELK in cell cycle progression, we assessed the effect of continuous OTSSP167 treatment on 
RAW264.7 and human PBMC viability and found that the viability of both osteoclast progenitor 
populations decreased (IC50: 12.8 nM and 43.2 nM respectively) (Fig 1C). This coincided with 
an induction of G2/M cell cycle arrest (Supplemental Fig 1A). The decrease in progenitor 
viability corresponded with a decrease in both human (Fig 1D and 1F) and murine (Fig 1E and 
1H) osteoclast differentiation following continuous OTSSP167 treatment. Although the number 
of osteoclasts decreased, osteoclast size was markedly increased in human cultures treated with 
10 nM OTSSP167, with a corresponding increase in the number of nuclei per osteoclasts (Fig 
1G). This was not the case for RAW264.7 osteoclast cultures (Fig 1I).  
 
OTSSP167 inhibits bone matrix resorption  
Bone matrix resorption decreased following OTSSP167 treatment of both primary human (Fig 
2A and 2C) and murine (Fig 2B and 2D) osteoclast cultures. Of note, this effect was apparent in 
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human osteoclasts treated with 10 nM OTSSP167, suggesting that the enlarged osteoclasts that 
are present at this concentration are not efficiently resorbing matrix. Similarly, murine osteoclast 
bone resorption was inhibited at 1 nM OTSSP167, a concentration at which no effect on 
osteoclast differentiation was observed. The blocking effect of OTSSP167 on osteoclast 
differentiation was confirmed at mRNA level, where we observed an increased expression of the 
negative regulator IRF8 and decreased expression of NFATC1 and DCSTAMP (Fig 2E). On the 
other hand, we detected an increase in EZH2 mRNA and protein levels, while the 
phosphorylation level of FOXM1 decreased (Supplemental Fig 1B). Finally, we observed no 
difference in actin ring formation in mature osteoclasts following OTSSP167 treatment (Fig 2F).  
 
Established osteoclast cultures are sensitive to OTSSP167 
In order to confirm that the effects of OTSSP167 on osteoclast function are not solely due to a 
decrease in monocyte viability, we initiated treatment of mature RAW264.7 osteoclasts after the 
final day of differentiation (day 5). In this setting, treatment with up to 10 nM OTSSP167 had no 
effect on the number of osteoclasts (Fig 3A and 3C). Initiation of OTSSP167 treatment on day 5 
or day 7 of in vitro matrix resorption assays markedly reduced bone matrix resorption (Fig 3B 
and 3D). Mature osteoclasts appeared at day 5 in these cultures and the presence of mature 
osteoclasts at the end of both DMSO- and OTSSP167-treated cultures was confirmed (not 
shown). Twenty-four hour treatment of mature osteoclasts had no impact on NFATc1 or TRAP 
mRNA levels (Fig 3E). However, we found OTSSP167 greatly reduced CTSK expression and 
greatly increased calcitonin receptor (CALCR) expression by mature osteoclasts (Fig 3E). 
Finally, as multiple reports indicate that both osteoclast differentiation and bone resorption by 
osteoclasts depend on the generation of reactive oxygen species (ROS)(23, 24), we assessed 
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whether OTSSP167 could hamper the generation of ROS by mature osteoclasts and this was 
indeed the case (Fig 3F).  
 
OTSSP167 stimulates osteoblast function 
Contrary to osteoclasts, MELK, EZH2 and FOXM1 expression decreased during OB formation 
indicating an inhibitory role in OB development (Fig 4A). These data suggest an opposing role 
for these molecules in OB formation which is in line with the results obtained with OTSSP167. 
Treatment of BMSC-TERT with OTSSP167 for 24 hours resulted in decreased MELK, EZH2 
and FOXM1 protein levels (Fig 4B). Although monocyte viability was considerably reduced 
following OTSSP167 treatment in the low nanomolar range, bone marrow stromal cell viability 
was unaffected at these concentrations (IC50: 800.2 nM) (Fig 4C). Accordingly, no G2/M cell 
cycle arrest was detected (Supplemental Fig 1A). Functionally, OTSSP167 increased collagen 
deposition by osteoblasts (Fig 4D and 4E) and induced a marked increase in matrix 
mineralization (Fig 4D and 4F). Finally, we determined the effect of OTSSP167 on osteoblast 
marker gene expression and found that osterix (OSX) expression was increased. Conversely 
RUNX2, osteopontin (OPN) and interleukin-6 (IL-6) expression were decreased (Fig 4G).   
 
Preclinical activity of OTSSP167 in multiple myeloma bone disease 
Our in vitro data indicate that OTSSP167 blocks osteoclast activity while stimulating osteoblast 
activity. Therefore, we assessed the potential of OTSSP167 as a novel therapy for MMBD in 
vivo in the 5TGM.1 MM model. The effects of OTSSP167 on myeloma development are given 
and discussed in detail in a separate publication.(7) OTSSP167 treatment prevented the 
development of MMBD and this effect was similar at all dosing schedules tested (Fig 5A). 
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OTSSP167 reduced the number of cortical perforations in MM-bearing mice (Fig 5B), without 
affecting cortical thickness (Ct.Th) (Supl Fig 1E) . The loss of trabecular bone volume 
(Tb.BV/TV) that occurs in MM-bearing mice compared to healthy controls, was completely 
prevented following treatment with OTSSP167 (Fig 5C). This was due to an increase in the 
number of trabeculae (Tb.N) (Fig 5D) and a decrease in trabecular separation (Tb.Sp) (Supl Fig 
1F). As a result, trabecular connectivity density (Conn.Dn) was similar to healthy mice in 
OTSSP167-treated MM-bearing mice (Supl Fig 1G). Trabecular thickness was not affected in 
MM-bearing mice (Supl Fig 1H). Importantly, the observed prevention of MMBD in these mice 
does not appear to be solely due to a decreased tumor load following OTSSP167 treatment, as 
MMBD was prevented at a dose (7.5 mg/kg/2d) which had no effect on tumor load (Fig 5E).  
 
OTSSP167 decreases osteoclast activity and restores osteoblast activity in multiple myeloma-
bearing mice 
Because of the lack of an anti-myeloma effect with an OTSSP167 dose of 7.5 mg/kg/2d, we 
performed immunohistomorphometry on the bones of mice from this cohort. The increase in 
osteoclast surface observed in MM-bearing mice was completely prevented after OTSSP167 
treatment (Fig 6A and 6D). Together with an increase in osteoclast activity, osteoblast surface 
was suppressed in MM-bearing mice and OTSSP167 restored osteoblast surface levels to those 
observed in naive mice (Fig 6B and 6E). Finally, given the effect of OTSSP167 on osteoblast 
collagen deposition and mineralizing activity in vitro, we analyzed osteoid and found that 
OTSSP167 increased osteoid surface in MM-bearing mice (Fig 6C and 6F). In addition, osteoid 





In this preclinical study, we demonstrated that MELK inhibitor OTSSP167 is a promising novel 
therapeutic agent for MMBD since OTSSP167 treatment blocked osteoclast activity and 
stimulated osteoblast activity in vitro, and completely prevented the development of MMBD in 
MM-bearing mice.  
 Consistent with an osteoclast stimulating activity of factors downstream of MELK, 
MELK mRNA levels increased during osteoclastogenesis. In addition we found significant 
mRNA changes in EZH2 and the negative regulator IRF8 known to influence the crucial 
differentiation factor NFATC1 which was found to be upregulated during osteoclast 
differentiation (illustrated in Supplemental Fig 1C). OTSSP167 decreased MELK protein levels 
in RAW264.7 cells, which agrees with previous studies on various cell types.(25, 26) Of note, 
OTSSP167 can have off-target effects, which could partially account for the effects of 
OTSSP167 on osteoclast and osteoblast function.(27, 28) In accordance with previous reports 
implicating MELK in G2/M transition and proliferation, OTSSP167 decreased the viability of 
monocytes due to G2/M cell cycle arrest.(26, 27, 29, 30) The decreased progenitor cell viability 
resulted in a decreased osteoclast differentiation following OTSSP167 treatment. It is difficult to 
differentiate between an anti-proliferative effect on progenitor cells and an anti-osteoclast 
differentiation effect. We observed that 2 pathways, known to interact with MELK, were 
affected by OTSSP167: i) the transcriptional factor FOXM1 which is implicated in proliferation 
and ii) the EZH2-IRF8-NFATC1 axis, involved in osteoclast differentiation. Unexpectedly, 
EZH2 levels increased, which can be explained by the strong link between cell cycle arrest and 
CDK1/2-dependent EZH2 phosphorylation on different residues (T487), which can either disrupt 
the binding of EZH2 to other partners of the polycomb repressive complex (31) or target it for 
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ubiquitin-mediated degradation (32). EZH2 becomes thus less functional, which results is a 
decline in H3K27 trimethylation and a de-repression of EZH2 target genes (in our case 
IRF8).(33) When mature osteoclasts were treated with OTSSP167, their numbers remained 
unaltered but matrix resorption was drastically decreased, further corroborating OTSSP167 has a 
direct effect on osteoclast activity. Together, our data indicate that OTSSP167 inhibits osteoclast 
function by hampering monocytic progenitor viability as well as by directly inhibiting mature 
osteoclast function.  
 MELK, EZH2 and FOXM1 mRNA levels decreased during osteoblast differentiation, 
consistent with an inhibitory role of MELK and downstream factors such as EZH2 on osteoblast 
function.(16, 17)  Contrary to osteoclasts and various malignant cells, BMSC-TERT viability 
was not affected following OTSSP167 treatment at similar concentrations. OTSSP167 treatment 
increased collagen deposition and strongly stimulated mineralization activity of osteoblasts in 
vitro and this coincided with an increase in OSX levels but a decrease in RUNX2, OPN and IL-6 
mRNA levels. The pro-mineralization activity of OTSSP167 is likely mediated by EZH2 as 
treatment with an EZH2 inhibitor showed a similar effect.(16) However, the decrease in RUNX2 
expression following OTSSP167 treatment does not correspond with the described role of EZH2 
as a suppressor of RUNX2 transcription.(16) Alternative mechanisms of OTSSP167 induced 
osteoblast maturation include a marked decrease in the expression of OPN, a non-collagenous 
bone matrix protein that inhibits matrix mineralization (34)  and IL-6, a(34)  and IL-6, potent 
growth factor for MM cells, but also a negative regulator of osteoblast differentiation (35) and 
inducer of bone resorption.(36) Deregulation of these genes in conjunction with the above 
mentioned upregulation of OSX, a master regulator of mineralization, likely mediates the pro-
osteogenic activity of OTSSP167. 
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 The regulation of MELK expression and activity by upstream signaling pathways 
remains poorly understood including in bone cells. E2F1 (37) and FOXM1 (10) have been 
shown to regulate MELK gene transcription, the former in osteoblastic MC3T3-E1 cells. Of note, 
E2F1 has been implicated in increased osteoclastogenesis and osteoblast activity (38, 39). MELK 
both regulates and is regulated by one family of MAP kinases, the c-Jun NH(2)-terminal kinases 
(JNK2), that acts downstream of the RANK-receptor (40). Interestingly, JNK2 does not seem to 
be required for osteoclast differentiation, but rather appears to be involved in osteoclast survival 
(41). 
 Given the promising in vitro data, we assessed whether OTSSP167 would affect the 
development of MMBD in the murine 5TGM.1 MM model. Although this model reflects human 
myeloma and associated bone disease in an immunocompetent setting, it should be noted that 
MM growth in this model progresses rapidly. This cell line allows in vivo studies, however also 
shows a BM-independent growth in vitro and its murine origin may not reflect all the human 
aspects of myeloma disease (from cytogenetic and molecular point of view). We have previously 
shown that the dosing schemes we used dose-dependently decreased MM tumor load.(7) 
OTSSP167 completely prevented the development of MMBD at all doses, with no difference 
between the treatment groups. Both the development of lytic cortical lesions and the large loss of 
trabecular bone were completely prevented in MM-bearing mice treated with OTSSP167. 
Importantly, this effect also occurred at an OTSSP167 concentration which had no effect on MM 
tumor load (7.5 mg/kg/2d), indicating that OTSSP167 has a direct effect on bone cells and does 
not solely reduce MMBD by reducing MM tumor load. In fact, given the lower concentration of 
OTSSP167 needed to achieve an anti-MMBD effect, our data suggest that OTSSP167 could 
exert its anti-MM effect in part by normalizing bone homeostasis. Indeed the reduced osteoclast 
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numbers following OTSSP167 treatment likely result in reduced myeloma pro-survival factor 
levels and increased myeloma anti-proliferative factor levels, respectively. Upon treatment with 
OTSSP167 we found decreased mRNA expression levels of insulin-like growth factor 1 (IGF-1), 
osteopontin, a proliferation-inducing ligand (APRIL) and interleukin-10 (IL-10) (supplemental 
Fig 1D)  
 
In conclusion, this study provides a novel approach for the treatment of MMBD. The 
maintenance of bone anabolic activity by OTSSP167 is promising and warrants further 
investigation. Reducing MM patient morbidity and mortality via the combined anti-MM and 
anti-MMBD effect of OTSSP167 holds great clinical promise and our results warrant similar 
studies in other cancers with bone involvement.  
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Figure legends 
Figure 1. OTSSP167 hampers osteoclast differentiation. A) mRNA levels of MELK, EZH2, 
FOXM1 and relevant transcription factors during osteoclastogenesis in murine cultures, MO: 
monocytes, OC: osteoclasts. B) The effect of OTSSP167 treatment on MELK protein expression 
in RAW264.7 cultures. C) MTT assay on PBMCs and RAW264.7 cells incubated with a range of 
OTSSP167 concentrations. D+E) Representative images of TRAP-stained human (huOC) and 
RAW264.7-derived osteoclast cultures continuously treated with a range of OTSSP167 
concentrations. F) Quantification of osteoclast numbers per field of view (N.OC/FOV) in huOC 
cultures. G) Number of nuclei per osteoclast in huOC cultures. H) Quantification of N.OC/FOV 
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in RAW264.7-derived cultures. I) Number of nuclei per osteoclast in RAW264.7-derived 
cultures. All data are represented as mean +/- standard error. *: p<0.05, **: p<0.01, ***: 
p<0.001. For clarity, only significant differences with vehicle-treated cultures are shown.  
 
Figure 2. OTSSP167 inhibits bone matrix resorption. A+B) Representative images of Von 
Kossa-stained bone matrix resorption assays of huOC and RAW264.7-derived osteoclast cultures 
continuously treated with a range of OTSSP167 concentrations. C+D) Quantification of the 
matrix resorption area in huOC and RAW264.7-derived osteoclast cultures. E) Real-time PCR 
analysis of MELK, IRF8, DC-STAMP and NFATc1 following OTSSP167 treatment of 
RAW264.7-derived osteoclast cultures. F) Representative confocal microscopy images of 
phalloidin-FITC-stained RAW264.7-derived osteoclast cultures. All data are represented as 
mean +/- standard error. *: p<0.05, **: p<0.01, ***: p<0.001. For clarity, only significant 
differences with vehicle-treated cultures are shown. 
 
Figure 3. Established osteoclast cultures are sensitive to OTSSP167. A) Representative 
images of TRAP-stained RAW264.7-derived osteoclast cultures treated with a range of 
OTSSP167 concentrations. Treatment of these cultures was initiated after the final day of 
osteoclast differentiation (day 5). B) Representative images of Von Kossa-stained bone matrix 
resorption assays of huOC and RAW264.7-derived osteoclast cultures treated with a range of 
OTSSP167 concentrations. Treatment of these cultures was initiated when mature osteoclasts 
appeared (early: day 5, late: day 7). C) Quantification of osteoclast numbers per field of view 
(N.OC/FOV) in RAW264.7-derived cultures treated with OTSSP167 starting at day 5. D) 
Quantification of the matrix resorption area in RAW264.7-derived osteoclast cultures treated 
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with OTSSP167 starting at day 5 or day 7. E) Real-time PCR analysis of osteoclast 
differentiation markers following OTSSP167 treatment starting at day 5 of RAW264.7-derived 
osteoclast cultures. F) ROS generation by RAW264.7-derived osteoclasts treated with 
OTSSP167 starting on day 5. All data are represented as mean +/- standard error. *: p<0.05, **: 
p<0.01, ***: p<0.001. 
 
Figure 4. OTSSP167 stimulates osteoblast function. A) MELK, EZH2 and FOXM1 mRNA 
levels during osteoblast differentiation of BMSC-TERT cells. B) The effect of OTSSP167 
treatment on MELK, EZH2 and FOXM1 protein levels in BMSC-TERT osteoblast cultures. C) 
MTT assay on BMSC-TERT cells incubated with a range of OTSSP167 concentrationsD) 
Representative images of sirius red (top panels) and alizarin red (bottom panels) stainings of 
BMSC-TERT osteoblast cultures treated with a range of OTSSP167 concentrations. E) 
Quantification of collagen deposition by BMSC-TERT osteoblasts following OTSSP167 
treatment. F) Quantification of matrix mineralization by BMSC-TERT osteoblasts following 
OTSSP167 treatment. G) Real-time PCR analysis of osteoblast differentiation marker expression 
by BMSC-TERT osteoblasts following OTSSP167 treatment. All data are represented as mean 
+/- standard error. *: p<0.05, **: p<0.01, ***: p<0.001. Except for panel A, only significant 
differences with vehicle-treated cultures are shown for clarity. 
 
Figure 5. Preclinical activity of OTSSP167 in multiple myeloma bone disease. A) 
Representative 3D-reconstructions of distal femurs of naive or 5TGM.1 MM-bearing mice 
treated with vehicle solution or various dosing schedules of OTSSP167. Upper panels show a 
frontal view. Lower panels show a frontal section of the frontal view. Cortical bone is colored 
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white, trabecular bone is colored green. B) Quantification of the number of cortical perforations 
with a diameter of at least 50 μm. CTAn analysis was performed and C) cortical thickness 
(Ct.Th), D) trabecular bone volume (Tb.BV/TV), E) trabecular number (Tb.N), F) trabecular 
separation (Tb.Sp), G) trabecular connectivity density (Conn.Dn) and H) trabecular thickness 
(Tb.Th) are reported here. I) Superimposition of tumor load data (red line, relative to vehicle-
treated MM-bearing mice) and Tb.BV/TV (black bars, relative to naive mice) in the different 
mouse cohorts. All data are represented as mean +/- standard error. All statistical differences are 
reported versus vehicle-treated mice. No difference between the different dosing schedules was 
observed. *: p<0.05, **: p<0.01, ***: p<0.001.  
 
Figure 6. OTSSP167 decreases osteoclast activity and restores osteoblast activity in 
multiple myeloma-bearing mice. A) Representative images of TRAP-stained distal femur 
sections of naive, vehicle- and OTSSP167-treated mice from the 7.5 mg/kg/2d cohort, which 
showed no effect on MM tumor load. 40X amplifications are shown in the inserts. B) 
Representative images of toluidine blue-stained distal femur sections from the same cohort. C) 
Representative images of Masson’s trichrome stained distal femur sections from the same cohort. 
D) Quantification of osteoclast surface (Oc.S/BS). E) Quantification of osteoblast surface 
(Ob.S/BS). F) Quantification of osteoid surface (OS/BS). G) Quantification of osteoid thickness 








 Supplemental figure 1: (A) Cell cycle analysis demonstrating G2/M cell cycle arrest following treatment of 
RAW264.7 cells and BMSC-TERT with OTSSP167. (B) Western blots for MELK, FOXM1, EZH2 and tubulin realized on 
protein samples obtained from RANKL-stimulated RAW264.7 cells, treated with different concentrations of 
OTSSP167 (C) Diagram illustrating the pathways regulated by MELK in osteoclast differentiation. (D)  mRNA 
expression of IGF-1, OPN, IL-10 and APRIL by RANKL-stimulated RAW264.7 cells, treated with different 
concentrations of OTSSP167. (E) Bone parameters obtained by CTAn analysis on µCT results illustrating cortical 
thickness (Ct.Th), (F) trabecular separation (Tb.Sp), (G)  trabecular connectivity density (Conn.Dn) and (H)  




Supplemental table 1: Sequences of primers used for qRT-PCR. 
 
